Revolutionizing Cancer Care and Inflammation Treatment – Invest in Groundbreaking Healthcare Innovations

Crowdfunding Has Never Been This Easy

Invst Guru is your bi-weekly digest that explores the dynamics of equity crowdfunding. Delivered every Wednesday and Sunday, we connect startups with the power of the crowd and provide investors with access to groundbreaking ventures.

In each issue of Invst Guru, we'll spotlight the latest trends, share success stories, and offer insights from industry leaders. We aim to equip you with the knowledge and opportunities to participate effectively in equity crowdfunding, whether you're looking to fund your innovative startup or invest in potential unicorns.

Genomic Expression Overview: Revolutionizing Cancer Treatment with RNA Technology

Genomic Expression is transforming cancer care through its innovative RNA platform, OneRNA®, which enables individualized treatment plans for breast and ovarian cancer patients. By analyzing a patient's complete RNA profile, the platform provides real-time data on active disease, offering a more precise and personalized approach to cancer treatment than traditional DNA-based tests.

Key Features and Innovations:

• OneRNA® Platform: Analyzes all mRNAs across 20,000 genes, offering superior insights compared to DNA tests focusing on a limited number of genes (up to 500). This allows for more accurate identification of actionable drug targets, improving patient outcomes by matching tumors to FDA-approved drugs.

• Real-Time Insights: While DNA offers predictive data on disease risk, RNA reflects current disease activity, making it a superior tool for real-time diagnosis and treatment navigation.

• Repurposing Existing Drugs: The platform is designed to repurpose FDA-approved drugs based on the patient's unique RNA profile, enhancing the efficacy of treatments and reducing the toxicity associated with traditional therapies.

Market Potential:

Genomic Expression is targeting the $220 billion cancer care market. Traditional DNA tests often fail to provide actionable insights for a wide range of cancer patients, making OneRNA® a game-changing solution. The company’s approach has successfully identified actionable drug targets for nearly all breast and ovarian cancer patients in its clinical trials.

Achievements and Milestones:

• CLIA Certification: The platform is certified for clinical use, making it a valuable diagnostic and treatment navigation tool.

• Partnerships: Collaborations with prestigious institutions such as Rutgers, MD Anderson, Northwell, and the NCI, alongside partnerships with pharmaceutical companies, drive further development of RNA-based therapeutics and companion diagnostics.

• Funding and Revenue: Genomic Expression has secured $6.5M in grants and $1.7M in seed funding and has generated $4.5M in revenue to date. The company is also pursuing a $3M contract with the National Cancer Institute (NCI).

Team:

• Gitte Pedersen (CEO, Co-Founder): With a background in life sciences and former experience at Novo Nordisk, Pedersen brings expertise in RNA technology and innovation policy.

• Morten Lorentz Pedersen (CSO, Co-Founder): A genetics expert and serial entrepreneur with multiple patents, Pedersen is driving the company's scientific advancements.

• Kirsten Dinesen Bertelsen (Director, part-time): An experienced business strategist with a background in digitalization, Bertelsen contributes to Genomic Expression’s strategic growth and operations.

Investment Opportunity:

• Investment Terms: The Reg CF offering is available via StartEngine. A minimum investment is $250, and the valuation cap is $50M.

• Positive Cash Flow and Growth: The company is in the commercial stage, aiming for positive cash flow through expanded sales, supported by a strong investor base and successful clinical validations.

Why Invest:

Investors can be part of a revolutionary platform reshaping cancer treatment and drug development. With a strong foundation in RNA technology, partnerships with leading institutions, and a proven ability to generate revenue, Genomic Expression is positioned to drive major advancements in precision oncology.

Invest in the future of cancer care with OneRNA®.

Today’s Sponsors 💰

Receive Honest News Today

Join over 4 million Americans who start their day with 1440 – your daily digest for unbiased, fact-centric news. From politics to sports, we cover it all by analyzing over 100 sources. Our concise, 5-minute read lands in your inbox each morning at no cost. Experience news without the noise; let 1440 help you make up your own mind. Sign up now and invite your friends and family to be part of the informed.

Sign up today!

Sen-Jam Pharmaceuticals Overview: Revolutionizing Inflammation Treatment

Sen-Jam Pharmaceuticals is a biotech company focused on creating innovative anti-inflammatory therapies that address the root causes of inflammation. By repurposing FDA-approved small molecules, Sen-Jam aims to bring safe, productive, and non-toxic treatments to market faster, preventing rather than masking inflammation, a significant driver of many major diseases.

Key Highlights:

• VC-Backed: Sen-Jam has raised over $250K from venture firms, demonstrating confidence in the company’s potential.

• Massive Addressable Market: The company is tapping into a $217B market across multiple therapeutic applications tied to inflammation-related diseases such as diabetes, cancer, opioid withdrawal, and alcohol hangover.

• Experienced Leadership Team: The team boasts over $730M in exits from companies associated with MIT, Harvard, Mayo Clinic, and Memorial Sloan Kettering, bringing a wealth of expertise and success to Sen-Jam’s development.

• Robust Patent Portfolio: With over 60 global patents granted or pending, Sen-Jam has secured a solid intellectual property position.

• Promising Clinical Pipeline: Sen-Jam has a portfolio of 11 assets, including 4 that are at or near pivotal Phase 2 clinical trials, addressing key areas like opioid withdrawal and alcohol hangovers.

Investment Opportunity:

Sen-Jam is currently in Tranche #3 of its fundraising campaign, with a $100M valuation. Investors in this phase are eligible for Fractional Royalty Rights (FRR) in licensing deals for the company’s alcohol hangover therapeutic, offering an attractive ROI with the potential for 11x returns. Additional incentives for investors include stock bonuses for contributions of $25,000 or more and special FRR rewards for referring new investors.

Market Potential:

Sen-Jam’s platform addresses inflammation, a core driver of diseases affecting over 150M Americans. The company is targeting a share of the $111B global anti-inflammatory drug market, which is growing at 9.3% CAGR. Beyond this, Sen-Jam estimates a $217B opportunity in therapeutic areas linked to inflammation, including respiratory infections, chronic pain, and even hangovers.

Leadership Team:

• Jim Iversen (Co-Founder, CEO): A serial entrepreneur with five successful exits totaling $80M. His expertise in scaling companies and his humanitarian approach to healthcare define Sen-Jam’s mission.

• Jackie Iversen (Co-Founder, Head of Clinical Development): A clinical research expert specializing in pharmacokinetics and pain management with a fellowship at Memorial Sloan Kettering.

• Thomas Dahl, PhD (Head of Product Development and Regulatory Affairs): A biochemistry and regulatory expert with experience at major pharmaceutical firms, including Johns Hopkins University.

Key Therapeutic Areas:

• Alcohol Hangover Treatment: Sen-Jam’s SJP-001 could be the first FDA-approved hangover cure, offering relief by addressing the inflammatory response caused by alcohol consumption.

• Opioid Withdrawal: The company’s innovative solution for opioid withdrawal focuses on reducing the inflammation that causes pain during the withdrawal process, potentially transforming treatment for millions suffering from opioid use disorder.

Why Invest:

Sen-Jam is positioned to lead a new category in the pharmaceutical industry, focusing on preventing inflammation-driven diseases. The company’s ability to repurpose small molecules already in use significantly reduces regulatory risks, making its path to market faster and more efficient. Investors support groundbreaking healthcare innovations and gain the potential for financial solid returns through equity, royalties, and licensing opportunities.

By investing in Sen-Jam, you join a mission to change how inflammation is treated globally, potentially improving the lives of 1 billion+ people while securing a foothold in a rapidly growing market.

Summary:

Sen-Jam Pharmaceuticals is creating a new approach to treating inflammation by developing affordable, effective, and preventative anti-inflammatory therapeutics. With a seasoned leadership team, robust patent portfolio, promising clinical assets, and massive market opportunity, Sen-Jam is poised to revolutionize healthcare.

Last Issues Poll Results 🗳️:

Would You Invest In Saxon Capital Group?

🟨🟨🟨🟨🟨🟨 👍 (1275)

🟩🟩🟩🟩🟩🟩 👎 (1306)

🟨🟨🟨🟨🟨⬜️ 🤷 (1229)

3810 Votes

Would You Invest In WeThrivv?

🟩🟩🟩🟩🟩🟩 👍 (1140)

🟨🟨🟨🟨🟨🟨 👎 (1119)

🟨🟨🟨🟨🟨⬜️ 🤷 (1008)

3267 Votes

Follow Our Friends 👀